Glycigon Tablet contains Gliclazide 80mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glycigon is prescribed as an adjunct to diet and exercise when these measures alone do not achieve adequate blood glucose regulation. The drug exhibits a selective action on pancreatic receptors, which contributes to a lower risk of hypoglycemia compared to other sulfonylureas. It is typically administered once daily, preferably with breakfast, to optimize efficacy and minimize adverse effects. Glycigon should be used cautiously in patients with renal or hepatic impairment, and dose adjustments may be necessary. Common side effects include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Regular monitoring of blood glucose levels and periodic assessment of renal and hepatic function are recommended during therapy. Glycigon is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Patient adherence to lifestyle modifications alongside pharmacotherapy enhances therapeutic outcomes. Consult a healthcare professional before initiating or modifying treatment with Glycigon Tablet.